已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

类风湿性关节炎 医学 甲氨蝶呤 内科学 随机对照试验 荟萃分析 药理学
作者
Dan Ouyang,Yuan Zhi,Jie Zou,Yong Long Wang,Zheng Chen,Yu Ying Yang,Bin Zou,Xin Li,Jian Zhong Cao
出处
期刊:Frontiers in Pharmacology [Frontiers Media SA]
卷期号:13 被引量:8
标识
DOI:10.3389/fphar.2022.911810
摘要

Objectives: We aimed to estimate the effectiveness and safety of iguratimod (IGU) monotherapy or in combination with methotrexate (MTX) in treating rheumatoid arthritis (RA) to provide an evidence-primarily-based foundation for clinical application. Methods: We conducted a systematic review of the meta-analysis using eight databases and two clinical trial websites searching for randomized controlled trials (RCTs) from conception to 15 March 2022, based on outcomes of patients with RA treated with IGU. The evidence quality assessment of primary outcomes was evaluated by the GRADE tool, and RevMan 5.3 and StataMP 14.0 were used to perform this research. Results: A total of 4302 patients with RA from 38 RCTs was included in this research. Pooled results demonstrated as follows: 1) Compared with methotrexate (MTX) alone, IGU alone was superior in improving ACR20 and DAS28-ESR, while having no significant difference in ACR50 and ACR70 [ACR20: (RR 1.15, 95% CI 1.05-1.27, p = 0.004); ACR50: (RR 0.97, 95% CI 0.66-1.44, p = 0.88); ACR70: (RR 0.92, 95% CI 0.45-1.90, p = 0.83); DAS28-ESR: mean difference (MD) -0.15, 95% CI -0.27 to -0.03, p = 0.01]. 2) Compared with MTX alone, IGU + MTX was more effective in improving ACR20, ACR50, ACR70, and DAS28-ESR. [ACR20: (RR 1.24, 95% CI 1.14-1.35, p < 0.00001); ACR50: (RR 1.96, 95% CI 1.62-2.39, p <0.00001); ACR70: (RR 1.91, 95% CI 1.41-2.57, p < 0.0001)]; [DAS28-ESR: (MD) -1.43, 95% CI -1.73 to -1.12, p < 0.00001]. 3) Compared with MTX + leflunomide (LEF), ACR20, ACR50, ACR70, and DAS28-ESR of IGU + MTX had no significant difference [ACR20: (RR 1.06, 95% CI 0.94-1.19, p = 0.38); ACR50: (RR 1.10, 95% CI 0.66-1.84, p = 0.72); ACR70: (RR 1.20, 95% CI 0.45-3.20, p = 0.71); DAS28-ESR: (MD -0.02, 95% CI -0.13 to -0.10, p = 0.77)]. 4) Compared with MTX + hydroxychloroquine (HCQ), IGU + MTX was superior in improving DAS28-ESR (MD -2.16, 95% CI -2.53 to -1.79, p < 0.00001). 5) Compared with MTX + tripterygium glycosides (TGs), IGU + MTX was more effective in improving DAS28-ESR (MD -0.94, 95% CI -2.36 to 0.48, p = 0.19). 6) There were no significant differences in adverse events (AEs) between the groups of IGU vs. MTX (RR 0.96, 95% CI 0.71-1.31, p = 0.80), IGU + MTX vs. MTX (RR 1.10, 95% CI 0.90-1.35, p = 0.34), IGU + MTX vs. MTX + HCQ (RR 0.64, 95% CI 0.29-1.42, p = 0.27), and IGU + MTX vs. MTX + TGs (RR 0.75, 95% CI 0.28-2.02, p = 0.57). The incidence of AEs in the IGU + MTX group was lower than the MTX + LEF group (RR 0.83, 95% CI 0.71-0.98, p = 0.03). Conclusion: Compared to the MTX alone subgroup, IGU alone offers clear advantages in improving ACR20 and DAS28-ESR, despite the insufficient evidence for DAS28-ESR findings. IGU + MTX shows clear benefits in improving ACR20, ACR50, ACR70, and DAS28-ESR scores compared to standard therapies. When the intervention (IGU alone or IGU + MTX) lasted for 52 weeks, it demonstrated superior efficacy in improving ACR20 of patients without prominent adverse events. Notably, IGU or IGU + MTX has apparent advantages in improving ACR20 of first-visit RA, and IGU + MTX has obvious advantages in improving DAS28-ESR of refractory RA. Furthermore, IGU + MTX does not increase the risk of leukopenia, but it can decrease the risk of liver function tests (LFTs), regardless of the age or the stage of RA. Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42022295217.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助Chaelisa采纳,获得50
2秒前
红炉一点雪完成签到 ,获得积分10
2秒前
顶钻师发布了新的文献求助10
4秒前
Isabella610发布了新的文献求助30
5秒前
milkdrink完成签到,获得积分10
6秒前
8秒前
zhiruo发布了新的文献求助10
8秒前
yyc发布了新的文献求助10
8秒前
wu发布了新的文献求助10
9秒前
脑洞疼应助科研通管家采纳,获得10
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
彭于晏应助科研通管家采纳,获得10
10秒前
科研通AI2S应助科研通管家采纳,获得10
10秒前
乐乐应助科研通管家采纳,获得200
11秒前
SciGPT应助科研通管家采纳,获得10
11秒前
充电宝应助科研通管家采纳,获得10
11秒前
11秒前
11秒前
Jasper应助科研通管家采纳,获得10
11秒前
绵绵完成签到 ,获得积分10
14秒前
充电宝发布了新的文献求助10
16秒前
16秒前
16秒前
milkdrink发布了新的文献求助10
18秒前
戴哈哈发布了新的文献求助10
18秒前
yyc完成签到,获得积分10
19秒前
我心向明月完成签到,获得积分10
22秒前
Chaelisa发布了新的文献求助50
23秒前
我是老大应助戴哈哈采纳,获得10
24秒前
25秒前
28秒前
福同学发布了新的文献求助10
30秒前
Chaelisa完成签到,获得积分10
31秒前
科研通AI2S应助包李采纳,获得20
36秒前
nini完成签到,获得积分10
37秒前
ggsr完成签到 ,获得积分10
40秒前
福同学完成签到,获得积分10
40秒前
科研通AI2S应助包李采纳,获得20
40秒前
hawaii66完成签到 ,获得积分10
44秒前
47秒前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
New China Forges Ahead: Important Documents of the Third Session of the First National Committee of the Chinese People's Political Consultative Conference 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056349
求助须知:如何正确求助?哪些是违规求助? 2712892
关于积分的说明 7433585
捐赠科研通 2357851
什么是DOI,文献DOI怎么找? 1249112
科研通“疑难数据库(出版商)”最低求助积分说明 606850
版权声明 596195